Semaglutide Research for Weight Loss
An evidence-based overview of research examining Semaglutide in the context of weight loss. This page synthesizes findings from peer-reviewed literature.
Research Summary
Semaglutide is FDA-approved for chronic weight management (as Wegovy) and has demonstrated substantial efficacy in multiple Phase 3 trials. The STEP 1 trial showed 14.9% mean weight loss versus 2.4% with placebo at 68 weeks (N=1,961). The mechanism involves GLP-1 receptor activation in appetite-regulating brain regions, reducing hunger and increasing satiety. Higher dose studies (STEP UP, 7.2mg) reported 20.7% mean weight loss under its efficacy estimand in adults with obesity; that estimate should not be generalized across formulations, populations, or estimands. Semaglutide represents a significant advance in pharmacological obesity treatment. In the STEP 1 extension subset, participants regained about two-thirds of their prior weight loss during one year after semaglutide and structured lifestyle intervention stopped. STEP 4 was a separate randomized withdrawal trial.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.